2022
Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry
Nowatzke J, Guedeney P, Palaskas N, Lehmann L, Ederhy S, Zhu H, Cautela J, Francis S, Courand PY, Deswal A, Ewer SM, Aras M, Arangalage D, Ghafourian K, Fenioux C, Finke D, Peretto G, Zaha V, Zadok O, Tajiri K, Akhter N, Levenson J, Baldassarre L, Power J, Huang S, Collet JP, Moslehi J, Salem JE, contributors I, Aghel N, Alexandre J, Aonuma K, Asnani A, Behling J, Bilen M, Bottinor W, Cariou E, Chahine J, Chan W, Chauhan A, Cohen M, Crusz S, Fernando S, Florido R, Frigeri M, Fukushima S, Gaughan E, Geisler B, Gilstrap L, Grohe C, Guha A, Habib M, Haegler-Laube E, Haydon A, Hayek S, Hughes A, Imai R, Katsume Y, Kimura H, Lin L, Lenneman C, Leong D, Makker V, Martinez-Calle N, Moey M, Mohri M, Morimoto R, Moritoki Y, Narezkina A, Nicol M, Nooka A, Orimoloye O, Patel M, Perl M, Piriou N, Raikhelkar J, Raza Y, Rao A, Reddy S, Seki N, Stangl K, Stewart A, Stringer B, Tamarappoo B, Tamura Y, Thuny F, Tierney S, Tresorier R, Ullah W, Von Hunolstein J, Warner E, Weppler A. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry. European Journal Of Cancer 2022, 177: 197-205. PMID: 36030143, PMCID: PMC10165738, DOI: 10.1016/j.ejca.2022.07.018.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseImmune checkpoint blockersCoronary revascularizationArtery diseaseCAD groupInternational registryPrompt clinical diagnosisAcute coronary syndromeCoronary artery stenosisAdjustment of ageCause deathCoronary syndromeIndex hospitalisationSteroid administrationCheckpoint blockersCoronary angiographyArtery stenosisCoronary angiogramPoor outcomeSevere presentationRevascularizationPatientsCardiac pathologyClinical diagnosisMyocarditis
2021
Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience
Batra A, Patel B, Addison D, Baldassarre LA, Desai N, Weintraub N, Deswal A, Hussain Z, Brown SA, Ganatra S, Agarwala V, Parikh PM, Fradley M, Ghosh A, Guha A. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart 2021, 8: e001849. PMID: 34952868, PMCID: PMC8710909, DOI: 10.1136/openhrt-2021-001849.Peer-Reviewed Original ResearchConceptsCardiovascular adverse eventsAdverse Event Reporting SystemCombination therapyAntimicrotubular agentsVinca alkaloidsAdverse eventsDrug Administration Adverse Event Reporting SystemRoutine cardiovascular assessmentCardiovascular safety profilePolytomous logistic regressionEvent Reporting SystemAgent therapyCombination chemotherapyHeart failureRegistry experienceSafety profileCardiovascular assessmentHigh burdenInhibitor combinationsChemotherapeutic agentsTaxanesTherapyLogistic regressionMonotherapyReporting systemOutcomes in patients with anthracycline‐induced cardiomyopathy undergoing left ventricular assist devices implantation
Guha A, Caraballo C, Jain P, Miller PE, Owusu‐Guha J, Clark KAA, Velazquez EJ, Ahmad T, Baldassarre LA, Addison D, Weintraub NL, Desai NR. Outcomes in patients with anthracycline‐induced cardiomyopathy undergoing left ventricular assist devices implantation. ESC Heart Failure 2021, 8: 2866-2875. PMID: 33982867, PMCID: PMC8318466, DOI: 10.1002/ehf2.13362.Peer-Reviewed Original ResearchConceptsAnthracycline-induced cardiomyopathyIschemic cardiomyopathyCardiomyopathy patientsCF-LVADICM patientsLeft ventricular assist device implantationContinuous-flow LVAD implantationHigher major bleeding riskVentricular assist device implantationEnd-stage heart failureMechanically Assisted Circulatory SupportCox proportional hazards modelCF-LVAD implantationAcute kidney injuryMajor bleeding riskAssist device implantationEtiology of cardiomyopathyProportional hazards modelBleeding riskKidney injuryInteragency RegistryLVAD implantationMajor infectionMedian survivalRespiratory support
2013
Mitral Apparatus Assessment by Delayed Enhancement CMR Relative Impact of Infarct Distribution on Mitral Regurgitation
Chinitz JS, Chen D, Goyal P, Wilson S, Islam F, Nguyen T, Wang Y, Hurtado-Rua S, Simprini L, Cham M, Levine RA, Devereux RB, Weinsaft JW. Mitral Apparatus Assessment by Delayed Enhancement CMR Relative Impact of Infarct Distribution on Mitral Regurgitation. JACC Cardiovascular Imaging 2013, 6: 220-234. PMID: 23489536, PMCID: PMC4048744, DOI: 10.1016/j.jcmg.2012.08.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnterior Wall Myocardial InfarctionChi-Square DistributionContrast MediaEchocardiography, Doppler, ColorEchocardiography, Doppler, PulsedFemaleHumansInferior Wall Myocardial InfarctionLogistic ModelsMagnetic Resonance Imaging, CineMaleMiddle AgedMitral ValveMitral Valve InsufficiencyMultivariate AnalysisMyocardiumOdds RatioPapillary MusclesPredictive Value of TestsProspective StudiesRegistriesRisk AssessmentRisk FactorsTime FactorsConceptsPapillary muscle infarctionAcute myocardial infarctionDelayed-enhancement cardiac magnetic resonanceMitral regurgitationInfarct distributionCulprit vesselMuscle infarctionPapillary musclesLateral wall infarctionLV end-diastolic diameterFirst acute myocardial infarctionGreater mitral regurgitationEnd-diastolic diameterCardiac magnetic resonanceMitral annular diameterLeft ventricular wallRight coronaryLeft circumflexInfarct patternsMultivariable analysisInfarct sizeMyocardial infarctionBasis of presenceWall injuryLV size